We provide new solutions based on the human microbiome for sufferers of serious chronic diseases for which there is currently no other therapy.
We are a bio-pharmaceutical company founded to conduct research into and develop medicines based on the human microbiome and provide new solutions in serious, chronic diseases for which there is currently no other therapy. We aspire to lead the paradigm shift entailed by designing therapeutic solutions based on the human microbiome and to be the first company in the world to market a medicine based on faecal microbiota in the EU.Learn more
Faecal Microbiota Transplantation
FMT consists of transferring intestinal microbiota via faecal material from a healthy donor to the gastrointestinal tract of a sick recipient in order to re-establish the balance of the latter’s intestinal microbiota.
Multiple clinical trials have shown FMT to be a safe, highly effective procedure for treating recurrent C. difficile infection.
WE DEVELOP MEDICINES
C. difficile is the main pathogen responsible for acquired diarrhoea in hospitalised patients, which is known as C. difficile infection (CDI) and accounts for 20% of antibiotic-associated diarrhoea and colitis cases. The incidence of CDI has been increasing, both in hospitalised patients and in the community. This is partly due to the appearance of hypervirulent strains, but also to improvements in diagnostic methods and the sometimes non-rational use of antibiotics.More information